AVILEX PHARMA

Avilex Pharma is a clinical stage company supported by venture capital and national foundations, with experienced researchers and pharmaceutical veterans... Avilex Pharma is also developing a pipeline of neuroprotectants for multiple Indications. Inhibition of PSD-95 has been clinically validated and AVLX-144 provides a unique opportunity for orphan and broad indications... Avilex Pharma is developing AVLX-144, a PSD-95 inhibitor and best-in-class neuroprotectant to treat patients suffering from acute conditions such as subarachnoid hemorrhage and acute ischemic stroke.

Primary location: Copenhagen Denmark